Literature DB >> 26564117

Atypical CML with massive splenic infarct: an extremely rare presentation.

Dhrubajyoti Bandyopadhyay1, Satyaki Manna2, Adrija Hajra2, Tanima Das Bhattacharya2.   

Abstract

We report a case of a 47-year-old man who presented with hepatosplenomegaly, anaemia and massive splenic infarct. A series of investigations led us to a diagnosis of atypical chronic myeloid leucaemia, a rare variety of a mixed myelodysplastic/myeloproliferative neoplasm. This is the first case of atypical CML presenting with massive splenic infarction. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26564117      PMCID： PMC4654048          DOI： 10.1136/bcr-2015-212821

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  11 in total

Review 1.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

2.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

Review 3.  Morphology and classification of the myelodysplastic syndromes and their pathologic variants.

Authors:  P A Kouides; J M Bennett
Journal:  Semin Hematol       Date:  1996-04       Impact factor: 3.851

Review 4.  Juvenile myelomonocytic leukemia.

Authors:  M Aricò; A Biondi; C H Pui
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 6.  Myelofibrosis with myeloid metaplasia.

Authors:  Giovanni Barosi
Journal:  Hematol Oncol Clin North Am       Date:  2003-10       Impact factor: 3.722

Review 7.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Authors:  Ross L Levine; Animesh Pardanani; Ayalew Tefferi; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

8.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H Gralnick; C Sultan; C Cox
Journal:  Br J Haematol       Date:  1994-08       Impact factor: 6.998

9.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

10.  Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?

Authors:  D G Oscier
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.